Predictors of Pulmonary Hypertension in Patients With Hypersensitivity Pneumonitis
NCT05458635 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60
Last updated 2022-07-14
Summary
Hypersensitivity pneumonitis (HP) is a complex immune mediated disorders caused by repeated inhalation of and sensitization to wide range of antigens including organic particles and chemical compounds, leading to exaggerated immuneresponse. Hypersenstivity pneumonitis is a common form of diffuse parenchymal lung diseases in Egypt .Pulmonary hypertension has been found as a complication of a number of diseases affecting the lung interstitium, including hypersensitivity pneumonitis, with subsequent affection of the life expectancy Rationale of the study: to find predictors for the development of pulmonary hypertension in patients with hypersensitivity pneumonitis
Conditions
- Pulmonary Hypertension
- Hypersensitivity Pneumonitis
Interventions
- PROCEDURE
-
Right heart catheter
Right heart catheterization was performed for 4 cases with high probability of pulmonary hypertension using multi-lumen swan ganz catheter.
Sponsors & Collaborators
-
Cairo University
lead OTHER
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 29 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-08-01
- Primary Completion
- 2020-10-31
- Completion
- 2021-03-15
Countries
- Egypt
Study Locations
More Related Trials
-
Discovering Clinical Study Experiences of Patients With Pulmonary Hypertension
NCT05918458 ·Status: NOT_YET_RECRUITING
-
Evaluation of Lung Doppler Signals in Pulmonary Hypertension
NCT01839786 ·Status: TERMINATED
-
What is the Role of the Exposome in Pulmonary Hypertension
NCT07172334 ·Status: NOT_YET_RECRUITING
-
The Safety of Flexible Bronchoscopy in Patients With Pulmonary Hypertension
NCT00986869 ·Status: UNKNOWN
-
Endothelial Function in Patients With Pulmonary Arterial Hypertension
NCT01317134 ·Status: COMPLETED ·Phase: NA
-
Medication Reconciliation in Pulmonary Hypertension
NCT04744584 ·Status: COMPLETED
-
FDG Uptake and Lung Blood Flow in PAH Before and After Treatment With Ambrisentan
NCT02958358 ·Status: WITHDRAWN ·Phase: NA
-
129 Xenon Imaging in Patients Treated With Sotatercept
NCT06351345 ·Status: RECRUITING ·Phase: PHASE2
-
Effects of Treprostinil on Right Ventricular Structure and Function in Patients With Pulmonary Arterial Hypertension
NCT03835676 ·Status: RECRUITING ·Phase: PHASE4
-
Effect of Endothelin-1 Receptor Blockade on Circulating Endothelial Microparticles Levels in Patients With Pulmonary Hypertension
NCT00675051 ·Status: COMPLETED
-
DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT06388421 ·Status: RECRUITING
-
Oxygen Treatment and Pulmonary Arterial Hypertension
NCT03683082 ·Status: UNKNOWN ·Phase: NA
-
A Study of HS135 for the Treatment of Pulmonary Arterial Hypertension in Adults
NCT06493461 ·Status: TERMINATED ·Phase: PHASE1
-
Empagliflozin in Pulmonary Arterial Hypertension
NCT05493371 ·Status: COMPLETED ·Phase: PHASE2
-
Feasibility of Slow-paced Respiration Therapy for Treatment of a Symptom Cluster in Pulmonary Arterial Hypertension
NCT02080533 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Efficacy and Safety of Triple-targeted Drug Therapy in Treatment-naive Patients With Non-low-risk PAH: A Real-world, Multicenter Study
NCT06753981 ·Status: RECRUITING
-
National Registry and Cohort Study of Pulmonary Vascular Disease
NCT05368467 ·Status: RECRUITING
-
Point of Care Ultrasonography Assessment During Pulmonary Hypertension Clinic
NCT05332847 ·Status: COMPLETED ·Phase: NA
-
Evaluation of the Pulmonary Vascular Reactivity Test in Patients With Pulmonary Arterial Hypertension and a Cardiac Shunt
NCT02138708 ·Status: WITHDRAWN ·Phase: NA
-
Integrated Diagnostics Characterization of Right Ventricular Diastolic Flow Dynamics in Pulmonary Arterial Hypertension
NCT01491646 ·Status: COMPLETED
-
Efficacy Study of Cardizem in Pulmonary Arterial Hypertension
NCT01645826 ·Status: WITHDRAWN ·Phase: NA
-
Testing of HIV Protease Inhibitors to Suppress Inflammation and Improve Cardio Pulmonary Hemodynamics in Subjects With Pulmonary Arterial Hypertension
NCT02023450 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Evaluating Lung Doppler Signals in Patients With Systemic Sclerosis (SSc)
NCT02246348 ·Status: TERMINATED ·Phase: NA
-
Cardiopulmonary Function Assessment and NO-Based Therapies for Patients With Hemolysis-Associated Pulmonary Hypertension
NCT00352430 ·Status: COMPLETED ·Phase: PHASE1
-
Hydroxyurea in Pulmonary Arterial Hypertension
NCT01950585 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1